nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—PTGS1—Balsalazide—Crohn's disease	0.252	0.429	CbGbCtD
Irbesartan—PTGS1—Mesalazine—Crohn's disease	0.201	0.343	CbGbCtD
Irbesartan—PTGS1—Sulfasalazine—Crohn's disease	0.113	0.192	CbGbCtD
Irbesartan—CYP3A4—Prednisone—Crohn's disease	0.0211	0.0359	CbGbCtD
Irbesartan—JUN—mouth—Crohn's disease	0.00377	0.113	CbGeAlD
Irbesartan—UGT1A3—digestive system—Crohn's disease	0.00295	0.0881	CbGeAlD
Irbesartan—JUN—epithelium—Crohn's disease	0.0022	0.0656	CbGeAlD
Irbesartan—JUN—smooth muscle tissue—Crohn's disease	0.00212	0.0632	CbGeAlD
Irbesartan—JUN—skin of body—Crohn's disease	0.00209	0.0624	CbGeAlD
Irbesartan—EDNRA—mammalian vulva—Crohn's disease	0.00209	0.0623	CbGeAlD
Irbesartan—JUN—mammalian vulva—Crohn's disease	0.0019	0.0569	CbGeAlD
Irbesartan—JUN—Betamethasone—Prednisone—Crohn's disease	0.00181	0.5	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisone—Crohn's disease	0.00181	0.5	CbGdCrCtD
Irbesartan—JUN—lymphoid tissue—Crohn's disease	0.00169	0.0505	CbGeAlD
Irbesartan—JUN—digestive system—Crohn's disease	0.00167	0.0499	CbGeAlD
Irbesartan—AGTR1—epithelium—Crohn's disease	0.00165	0.0494	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—Crohn's disease	0.00159	0.0476	CbGeAlD
Irbesartan—AGTR1—lymphoid tissue—Crohn's disease	0.00127	0.038	CbGeAlD
Irbesartan—Pancreatitis—Mercaptopurine—Crohn's disease	0.00122	0.00654	CcSEcCtD
Irbesartan—Vasculitis—Azathioprine—Crohn's disease	0.00121	0.00649	CcSEcCtD
Irbesartan—Protein urine present—Mesalazine—Crohn's disease	0.00121	0.00647	CcSEcCtD
Irbesartan—Musculoskeletal stiffness—Mesalazine—Crohn's disease	0.0012	0.00643	CcSEcCtD
Irbesartan—Trauma—Prednisone—Crohn's disease	0.00119	0.00641	CcSEcCtD
Irbesartan—Gout—Mesalazine—Crohn's disease	0.00115	0.00618	CcSEcCtD
Irbesartan—Lymphopenia—Prednisone—Crohn's disease	0.00111	0.00596	CcSEcCtD
Irbesartan—Aplastic anaemia—Azathioprine—Crohn's disease	0.00111	0.00595	CcSEcCtD
Irbesartan—Musculoskeletal pain—Mesalazine—Crohn's disease	0.00109	0.00584	CcSEcCtD
Irbesartan—Epigastric discomfort—Prednisone—Crohn's disease	0.00108	0.0058	CcSEcCtD
Irbesartan—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.00105	0.00562	CcSEcCtD
Irbesartan—EDNRA—lymph node—Crohn's disease	0.00105	0.0312	CbGeAlD
Irbesartan—Blood urea increased—Mesalazine—Crohn's disease	0.00101	0.00545	CcSEcCtD
Irbesartan—Aplastic anaemia—Mesalazine—Crohn's disease	0.00101	0.00542	CcSEcCtD
Irbesartan—Hepatic function abnormal—Azathioprine—Crohn's disease	0.00098	0.00526	CcSEcCtD
Irbesartan—Ecchymosis—Mesalazine—Crohn's disease	0.000972	0.00521	CcSEcCtD
Irbesartan—JUN—lymph node—Crohn's disease	0.000954	0.0285	CbGeAlD
Irbesartan—Ear pain—Mesalazine—Crohn's disease	0.000915	0.00491	CcSEcCtD
Irbesartan—Immune system disorder—Mercaptopurine—Crohn's disease	0.000898	0.00482	CcSEcCtD
Irbesartan—Photosensitivity—Mesalazine—Crohn's disease	0.000889	0.00477	CcSEcCtD
Irbesartan—Gastroenteritis—Mesalazine—Crohn's disease	0.00088	0.00472	CcSEcCtD
Irbesartan—Malnutrition—Mercaptopurine—Crohn's disease	0.000866	0.00465	CcSEcCtD
Irbesartan—Increased appetite—Mesalazine—Crohn's disease	0.000831	0.00446	CcSEcCtD
Irbesartan—Renal impairment—Mesalazine—Crohn's disease	0.00082	0.0044	CcSEcCtD
Irbesartan—Arthritis—Mesalazine—Crohn's disease	0.000803	0.00431	CcSEcCtD
Irbesartan—Anaemia—Mercaptopurine—Crohn's disease	0.0008	0.00429	CcSEcCtD
Irbesartan—Leukopenia—Mercaptopurine—Crohn's disease	0.000775	0.00416	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.000771	0.00414	CcSEcCtD
Irbesartan—Affect lability—Mesalazine—Crohn's disease	0.000768	0.00412	CcSEcCtD
Irbesartan—Face oedema—Mesalazine—Crohn's disease	0.000753	0.00404	CcSEcCtD
Irbesartan—Mood swings—Mesalazine—Crohn's disease	0.000739	0.00397	CcSEcCtD
Irbesartan—Arthralgia—Mercaptopurine—Crohn's disease	0.000737	0.00396	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000732	0.00393	CcSEcCtD
Irbesartan—PTGS1—epithelium—Crohn's disease	0.000727	0.0217	CbGeAlD
Irbesartan—Pancreatitis—Azathioprine—Crohn's disease	0.000726	0.00389	CcSEcCtD
Irbesartan—Liver function test abnormal—Mesalazine—Crohn's disease	0.00072	0.00387	CcSEcCtD
Irbesartan—AGTR1—lymph node—Crohn's disease	0.000719	0.0215	CbGeAlD
Irbesartan—Orthostatic hypotension—Mesalazine—Crohn's disease	0.000713	0.00382	CcSEcCtD
Irbesartan—Abdominal pain upper—Mesalazine—Crohn's disease	0.000713	0.00382	CcSEcCtD
Irbesartan—Oedema—Mercaptopurine—Crohn's disease	0.000707	0.00379	CcSEcCtD
Irbesartan—Breast disorder—Mesalazine—Crohn's disease	0.000705	0.00378	CcSEcCtD
Irbesartan—Cramp muscle—Mesalazine—Crohn's disease	0.000703	0.00377	CcSEcCtD
Irbesartan—Glycosuria—Prednisone—Crohn's disease	0.000702	0.00377	CcSEcCtD
Irbesartan—PTGS1—smooth muscle tissue—Crohn's disease	0.0007	0.0209	CbGeAlD
Irbesartan—Nasopharyngitis—Mesalazine—Crohn's disease	0.000698	0.00374	CcSEcCtD
Irbesartan—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000692	0.00371	CcSEcCtD
Irbesartan—PTGS1—skin of body—Crohn's disease	0.000691	0.0206	CbGeAlD
Irbesartan—Skin disorder—Mercaptopurine—Crohn's disease	0.000686	0.00368	CcSEcCtD
Irbesartan—Abdominal distension—Mesalazine—Crohn's disease	0.000679	0.00364	CcSEcCtD
Irbesartan—Dysphagia—Mesalazine—Crohn's disease	0.000674	0.00362	CcSEcCtD
Irbesartan—Influenza—Mesalazine—Crohn's disease	0.000674	0.00362	CcSEcCtD
Irbesartan—Asthma—Mesalazine—Crohn's disease	0.000674	0.00362	CcSEcCtD
Irbesartan—Anorexia—Mercaptopurine—Crohn's disease	0.000674	0.00361	CcSEcCtD
Irbesartan—Pneumonia—Azathioprine—Crohn's disease	0.000664	0.00356	CcSEcCtD
Irbesartan—Pancreatitis—Mesalazine—Crohn's disease	0.000661	0.00355	CcSEcCtD
Irbesartan—Angina pectoris—Mesalazine—Crohn's disease	0.000657	0.00352	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000644	0.00345	CcSEcCtD
Irbesartan—CYP1A2—digestive system—Crohn's disease	0.000638	0.0191	CbGeAlD
Irbesartan—Neutropenia—Mesalazine—Crohn's disease	0.000631	0.00338	CcSEcCtD
Irbesartan—PTGS1—mammalian vulva—Crohn's disease	0.000631	0.0188	CbGeAlD
Irbesartan—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000627	0.00336	CcSEcCtD
Irbesartan—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000624	0.00335	CcSEcCtD
Irbesartan—Agranulocytosis—Azathioprine—Crohn's disease	0.000616	0.00331	CcSEcCtD
Irbesartan—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000616	0.0033	CcSEcCtD
Irbesartan—Decreased appetite—Mercaptopurine—Crohn's disease	0.000614	0.0033	CcSEcCtD
Irbesartan—Weight increased—Mesalazine—Crohn's disease	0.000614	0.00329	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00061	0.00327	CcSEcCtD
Irbesartan—CYP2C9—digestive system—Crohn's disease	0.000606	0.0181	CbGeAlD
Irbesartan—Pneumonia—Mesalazine—Crohn's disease	0.000605	0.00325	CcSEcCtD
Irbesartan—Renal failure—Mesalazine—Crohn's disease	0.000591	0.00317	CcSEcCtD
Irbesartan—Jaundice—Mesalazine—Crohn's disease	0.000586	0.00314	CcSEcCtD
Irbesartan—Urinary tract infection—Mesalazine—Crohn's disease	0.000585	0.00314	CcSEcCtD
Irbesartan—Conjunctivitis—Mesalazine—Crohn's disease	0.000585	0.00314	CcSEcCtD
Irbesartan—Vasculitis—Prednisone—Crohn's disease	0.000583	0.00313	CcSEcCtD
Irbesartan—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000569	0.00305	CcSEcCtD
Irbesartan—Epistaxis—Mesalazine—Crohn's disease	0.000567	0.00304	CcSEcCtD
Irbesartan—Agranulocytosis—Mesalazine—Crohn's disease	0.000561	0.00301	CcSEcCtD
Irbesartan—Body temperature increased—Mercaptopurine—Crohn's disease	0.000559	0.003	CcSEcCtD
Irbesartan—PTGS1—digestive system—Crohn's disease	0.000553	0.0165	CbGeAlD
Irbesartan—Rhinitis—Mesalazine—Crohn's disease	0.000541	0.0029	CcSEcCtD
Irbesartan—Hepatitis—Mesalazine—Crohn's disease	0.00054	0.0029	CcSEcCtD
Irbesartan—Pharyngitis—Mesalazine—Crohn's disease	0.000536	0.00287	CcSEcCtD
Irbesartan—Immune system disorder—Azathioprine—Crohn's disease	0.000535	0.00287	CcSEcCtD
Irbesartan—Mediastinal disorder—Azathioprine—Crohn's disease	0.000534	0.00287	CcSEcCtD
Irbesartan—Urinary tract disorder—Mesalazine—Crohn's disease	0.000533	0.00286	CcSEcCtD
Irbesartan—Oedema peripheral—Mesalazine—Crohn's disease	0.000532	0.00285	CcSEcCtD
Irbesartan—Chills—Azathioprine—Crohn's disease	0.000532	0.00285	CcSEcCtD
Irbesartan—Connective tissue disorder—Mesalazine—Crohn's disease	0.000531	0.00285	CcSEcCtD
Irbesartan—Arrhythmia—Azathioprine—Crohn's disease	0.000529	0.00284	CcSEcCtD
Irbesartan—Urethral disorder—Mesalazine—Crohn's disease	0.000529	0.00284	CcSEcCtD
Irbesartan—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000521	0.00279	CcSEcCtD
Irbesartan—Oesophagitis—Prednisone—Crohn's disease	0.00052	0.00279	CcSEcCtD
Irbesartan—Ecchymosis—Prednisone—Crohn's disease	0.000514	0.00276	CcSEcCtD
Irbesartan—Pulmonary oedema—Prednisone—Crohn's disease	0.000506	0.00272	CcSEcCtD
Irbesartan—Tinnitus—Mesalazine—Crohn's disease	0.000503	0.0027	CcSEcCtD
Irbesartan—Cardiac disorder—Mesalazine—Crohn's disease	0.000501	0.00269	CcSEcCtD
Irbesartan—Angiopathy—Mesalazine—Crohn's disease	0.00049	0.00263	CcSEcCtD
Irbesartan—Immune system disorder—Mesalazine—Crohn's disease	0.000488	0.00262	CcSEcCtD
Irbesartan—Mediastinal disorder—Mesalazine—Crohn's disease	0.000487	0.00261	CcSEcCtD
Irbesartan—Chills—Mesalazine—Crohn's disease	0.000484	0.0026	CcSEcCtD
Irbesartan—Diarrhoea—Mercaptopurine—Crohn's disease	0.000484	0.00259	CcSEcCtD
Irbesartan—Ill-defined disorder—Azathioprine—Crohn's disease	0.000479	0.00257	CcSEcCtD
Irbesartan—Anaemia—Azathioprine—Crohn's disease	0.000477	0.00256	CcSEcCtD
Irbesartan—Diabetes mellitus—Prednisone—Crohn's disease	0.000475	0.00255	CcSEcCtD
Irbesartan—Erythema—Mesalazine—Crohn's disease	0.00047	0.00252	CcSEcCtD
Irbesartan—Malaise—Azathioprine—Crohn's disease	0.000465	0.0025	CcSEcCtD
Irbesartan—Flatulence—Mesalazine—Crohn's disease	0.000463	0.00248	CcSEcCtD
Irbesartan—CYP3A4—digestive system—Crohn's disease	0.000462	0.0138	CbGeAlD
Irbesartan—Leukopenia—Azathioprine—Crohn's disease	0.000462	0.00248	CcSEcCtD
Irbesartan—Tension—Mesalazine—Crohn's disease	0.000461	0.00247	CcSEcCtD
Irbesartan—Dysgeusia—Mesalazine—Crohn's disease	0.00046	0.00247	CcSEcCtD
Irbesartan—Nervousness—Mesalazine—Crohn's disease	0.000456	0.00245	CcSEcCtD
Irbesartan—CYP2D6—digestive system—Crohn's disease	0.000455	0.0136	CbGeAlD
Irbesartan—Muscle spasms—Mesalazine—Crohn's disease	0.000452	0.00242	CcSEcCtD
Irbesartan—Vomiting—Mercaptopurine—Crohn's disease	0.000449	0.00241	CcSEcCtD
Irbesartan—Injury—Prednisone—Crohn's disease	0.000449	0.00241	CcSEcCtD
Irbesartan—Rash—Mercaptopurine—Crohn's disease	0.000446	0.00239	CcSEcCtD
Irbesartan—Dermatitis—Mercaptopurine—Crohn's disease	0.000445	0.00239	CcSEcCtD
Irbesartan—Vision blurred—Mesalazine—Crohn's disease	0.000443	0.00238	CcSEcCtD
Irbesartan—Tremor—Mesalazine—Crohn's disease	0.00044	0.00236	CcSEcCtD
Irbesartan—Increased appetite—Prednisone—Crohn's disease	0.000439	0.00236	CcSEcCtD
Irbesartan—Myalgia—Azathioprine—Crohn's disease	0.000439	0.00236	CcSEcCtD
Irbesartan—Arthralgia—Azathioprine—Crohn's disease	0.000439	0.00236	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000436	0.00234	CcSEcCtD
Irbesartan—Ill-defined disorder—Mesalazine—Crohn's disease	0.000436	0.00234	CcSEcCtD
Irbesartan—Anaemia—Mesalazine—Crohn's disease	0.000434	0.00233	CcSEcCtD
Irbesartan—Discomfort—Azathioprine—Crohn's disease	0.000434	0.00233	CcSEcCtD
Irbesartan—Angioedema—Mesalazine—Crohn's disease	0.000429	0.0023	CcSEcCtD
Irbesartan—Malaise—Mesalazine—Crohn's disease	0.000424	0.00227	CcSEcCtD
Irbesartan—Vertigo—Mesalazine—Crohn's disease	0.000422	0.00227	CcSEcCtD
Irbesartan—Syncope—Mesalazine—Crohn's disease	0.000421	0.00226	CcSEcCtD
Irbesartan—Leukopenia—Mesalazine—Crohn's disease	0.000421	0.00226	CcSEcCtD
Irbesartan—Nausea—Mercaptopurine—Crohn's disease	0.00042	0.00225	CcSEcCtD
Irbesartan—Infection—Azathioprine—Crohn's disease	0.000418	0.00224	CcSEcCtD
Irbesartan—Loss of consciousness—Mesalazine—Crohn's disease	0.000413	0.00222	CcSEcCtD
Irbesartan—Thrombocytopenia—Azathioprine—Crohn's disease	0.000412	0.00221	CcSEcCtD
Irbesartan—Valsartan—ALB—Crohn's disease	0.000412	0.672	CrCbGaD
Irbesartan—Cough—Mesalazine—Crohn's disease	0.00041	0.0022	CcSEcCtD
Irbesartan—Skin disorder—Azathioprine—Crohn's disease	0.000409	0.00219	CcSEcCtD
Irbesartan—Affect lability—Prednisone—Crohn's disease	0.000406	0.00218	CcSEcCtD
Irbesartan—Hypertension—Mesalazine—Crohn's disease	0.000406	0.00218	CcSEcCtD
Irbesartan—Chest pain—Mesalazine—Crohn's disease	0.0004	0.00215	CcSEcCtD
Irbesartan—Arthralgia—Mesalazine—Crohn's disease	0.0004	0.00215	CcSEcCtD
Irbesartan—Myalgia—Mesalazine—Crohn's disease	0.0004	0.00215	CcSEcCtD
Irbesartan—Anxiety—Mesalazine—Crohn's disease	0.000399	0.00214	CcSEcCtD
Irbesartan—Face oedema—Prednisone—Crohn's disease	0.000399	0.00214	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000397	0.00213	CcSEcCtD
Irbesartan—Discomfort—Mesalazine—Crohn's disease	0.000395	0.00212	CcSEcCtD
Irbesartan—Hypotension—Azathioprine—Crohn's disease	0.000393	0.00211	CcSEcCtD
Irbesartan—Dry mouth—Mesalazine—Crohn's disease	0.000391	0.0021	CcSEcCtD
Irbesartan—Mood swings—Prednisone—Crohn's disease	0.000391	0.0021	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000384	0.00206	CcSEcCtD
Irbesartan—Anaphylactic shock—Mesalazine—Crohn's disease	0.000384	0.00206	CcSEcCtD
Irbesartan—Oedema—Mesalazine—Crohn's disease	0.000384	0.00206	CcSEcCtD
Irbesartan—Infection—Mesalazine—Crohn's disease	0.000381	0.00204	CcSEcCtD
Irbesartan—Shock—Mesalazine—Crohn's disease	0.000377	0.00202	CcSEcCtD
Irbesartan—Nervous system disorder—Mesalazine—Crohn's disease	0.000376	0.00202	CcSEcCtD
Irbesartan—Hypokalaemia—Prednisone—Crohn's disease	0.000376	0.00202	CcSEcCtD
Irbesartan—Thrombocytopenia—Mesalazine—Crohn's disease	0.000376	0.00201	CcSEcCtD
Irbesartan—Tachycardia—Mesalazine—Crohn's disease	0.000374	0.00201	CcSEcCtD
Irbesartan—Skin disorder—Mesalazine—Crohn's disease	0.000373	0.002	CcSEcCtD
Irbesartan—Hyperhidrosis—Mesalazine—Crohn's disease	0.000371	0.00199	CcSEcCtD
Irbesartan—Anorexia—Mesalazine—Crohn's disease	0.000366	0.00196	CcSEcCtD
Irbesartan—Muscular weakness—Prednisone—Crohn's disease	0.000364	0.00195	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000364	0.00195	CcSEcCtD
Irbesartan—Abdominal distension—Prednisone—Crohn's disease	0.000359	0.00193	CcSEcCtD
Irbesartan—Hypotension—Mesalazine—Crohn's disease	0.000358	0.00192	CcSEcCtD
Irbesartan—Pancreatitis—Prednisone—Crohn's disease	0.00035	0.00188	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000349	0.00187	CcSEcCtD
Irbesartan—Feeling abnormal—Azathioprine—Crohn's disease	0.000347	0.00186	CcSEcCtD
Irbesartan—Paraesthesia—Mesalazine—Crohn's disease	0.000344	0.00185	CcSEcCtD
Irbesartan—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000344	0.00185	CcSEcCtD
Irbesartan—Dyspnoea—Mesalazine—Crohn's disease	0.000342	0.00183	CcSEcCtD
Irbesartan—Somnolence—Mesalazine—Crohn's disease	0.000341	0.00183	CcSEcCtD
Irbesartan—Dyspepsia—Mesalazine—Crohn's disease	0.000338	0.00181	CcSEcCtD
Irbesartan—Neutropenia—Prednisone—Crohn's disease	0.000334	0.00179	CcSEcCtD
Irbesartan—Decreased appetite—Mesalazine—Crohn's disease	0.000333	0.00179	CcSEcCtD
Irbesartan—Body temperature increased—Azathioprine—Crohn's disease	0.000333	0.00179	CcSEcCtD
Irbesartan—Abdominal pain—Azathioprine—Crohn's disease	0.000333	0.00179	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000331	0.00178	CcSEcCtD
Irbesartan—Fatigue—Mesalazine—Crohn's disease	0.000331	0.00177	CcSEcCtD
Irbesartan—Pain—Mesalazine—Crohn's disease	0.000328	0.00176	CcSEcCtD
Irbesartan—Constipation—Mesalazine—Crohn's disease	0.000328	0.00176	CcSEcCtD
Irbesartan—Weight increased—Prednisone—Crohn's disease	0.000325	0.00174	CcSEcCtD
Irbesartan—Hyperglycaemia—Prednisone—Crohn's disease	0.000322	0.00173	CcSEcCtD
Irbesartan—Feeling abnormal—Mesalazine—Crohn's disease	0.000316	0.0017	CcSEcCtD
Irbesartan—PTGS1—lymph node—Crohn's disease	0.000316	0.00943	CbGeAlD
Irbesartan—Acute coronary syndrome—Prednisone—Crohn's disease	0.000314	0.00168	CcSEcCtD
Irbesartan—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000314	0.00168	CcSEcCtD
Irbesartan—Myocardial infarction—Prednisone—Crohn's disease	0.000312	0.00167	CcSEcCtD
Irbesartan—Hypersensitivity—Azathioprine—Crohn's disease	0.00031	0.00166	CcSEcCtD
Irbesartan—Urticaria—Mesalazine—Crohn's disease	0.000305	0.00163	CcSEcCtD
Irbesartan—Abdominal pain—Mesalazine—Crohn's disease	0.000303	0.00163	CcSEcCtD
Irbesartan—Body temperature increased—Mesalazine—Crohn's disease	0.000303	0.00163	CcSEcCtD
Irbesartan—Bradycardia—Prednisone—Crohn's disease	0.000291	0.00156	CcSEcCtD
Irbesartan—Diarrhoea—Azathioprine—Crohn's disease	0.000288	0.00155	CcSEcCtD
Irbesartan—Hypersensitivity—Mesalazine—Crohn's disease	0.000283	0.00152	CcSEcCtD
Irbesartan—Connective tissue disorder—Prednisone—Crohn's disease	0.000281	0.00151	CcSEcCtD
Irbesartan—Dizziness—Azathioprine—Crohn's disease	0.000278	0.00149	CcSEcCtD
Irbesartan—Asthenia—Mesalazine—Crohn's disease	0.000275	0.00148	CcSEcCtD
Irbesartan—Pruritus—Mesalazine—Crohn's disease	0.000271	0.00146	CcSEcCtD
Irbesartan—Vomiting—Azathioprine—Crohn's disease	0.000268	0.00144	CcSEcCtD
Irbesartan—Rash—Azathioprine—Crohn's disease	0.000266	0.00142	CcSEcCtD
Irbesartan—Dermatitis—Azathioprine—Crohn's disease	0.000265	0.00142	CcSEcCtD
Irbesartan—Flushing—Prednisone—Crohn's disease	0.000265	0.00142	CcSEcCtD
Irbesartan—Headache—Azathioprine—Crohn's disease	0.000264	0.00142	CcSEcCtD
Irbesartan—Diarrhoea—Mesalazine—Crohn's disease	0.000262	0.00141	CcSEcCtD
Irbesartan—Angiopathy—Prednisone—Crohn's disease	0.000259	0.00139	CcSEcCtD
Irbesartan—Immune system disorder—Prednisone—Crohn's disease	0.000258	0.00138	CcSEcCtD
Irbesartan—Arrhythmia—Prednisone—Crohn's disease	0.000255	0.00137	CcSEcCtD
Irbesartan—Dizziness—Mesalazine—Crohn's disease	0.000254	0.00136	CcSEcCtD
Irbesartan—Nausea—Azathioprine—Crohn's disease	0.00025	0.00134	CcSEcCtD
Irbesartan—Erythema—Prednisone—Crohn's disease	0.000249	0.00133	CcSEcCtD
Irbesartan—Malnutrition—Prednisone—Crohn's disease	0.000249	0.00133	CcSEcCtD
Irbesartan—Vomiting—Mesalazine—Crohn's disease	0.000244	0.00131	CcSEcCtD
Irbesartan—Rash—Mesalazine—Crohn's disease	0.000242	0.0013	CcSEcCtD
Irbesartan—Dermatitis—Mesalazine—Crohn's disease	0.000242	0.0013	CcSEcCtD
Irbesartan—Headache—Mesalazine—Crohn's disease	0.00024	0.00129	CcSEcCtD
Irbesartan—Vision blurred—Prednisone—Crohn's disease	0.000234	0.00126	CcSEcCtD
Irbesartan—Ill-defined disorder—Prednisone—Crohn's disease	0.000231	0.00124	CcSEcCtD
Irbesartan—Anaemia—Prednisone—Crohn's disease	0.00023	0.00123	CcSEcCtD
Irbesartan—Agitation—Prednisone—Crohn's disease	0.000229	0.00123	CcSEcCtD
Irbesartan—Nausea—Mesalazine—Crohn's disease	0.000228	0.00122	CcSEcCtD
Irbesartan—Angioedema—Prednisone—Crohn's disease	0.000227	0.00122	CcSEcCtD
Irbesartan—Malaise—Prednisone—Crohn's disease	0.000224	0.0012	CcSEcCtD
Irbesartan—Vertigo—Prednisone—Crohn's disease	0.000223	0.0012	CcSEcCtD
Irbesartan—Syncope—Prednisone—Crohn's disease	0.000223	0.0012	CcSEcCtD
Irbesartan—Loss of consciousness—Prednisone—Crohn's disease	0.000219	0.00117	CcSEcCtD
Irbesartan—Hypertension—Prednisone—Crohn's disease	0.000215	0.00115	CcSEcCtD
Irbesartan—Myalgia—Prednisone—Crohn's disease	0.000212	0.00114	CcSEcCtD
Irbesartan—Arthralgia—Prednisone—Crohn's disease	0.000212	0.00114	CcSEcCtD
Irbesartan—Anxiety—Prednisone—Crohn's disease	0.000211	0.00113	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.00021	0.00113	CcSEcCtD
Irbesartan—Discomfort—Prednisone—Crohn's disease	0.000209	0.00112	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisone—Crohn's disease	0.000203	0.00109	CcSEcCtD
Irbesartan—Oedema—Prednisone—Crohn's disease	0.000203	0.00109	CcSEcCtD
Irbesartan—Infection—Prednisone—Crohn's disease	0.000202	0.00108	CcSEcCtD
Irbesartan—Losartan—ALB—Crohn's disease	0.000201	0.328	CrCbGaD
Irbesartan—Shock—Prednisone—Crohn's disease	0.0002	0.00107	CcSEcCtD
Irbesartan—Nervous system disorder—Prednisone—Crohn's disease	0.000199	0.00107	CcSEcCtD
Irbesartan—Tachycardia—Prednisone—Crohn's disease	0.000198	0.00106	CcSEcCtD
Irbesartan—Skin disorder—Prednisone—Crohn's disease	0.000197	0.00106	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—Crohn's disease	0.000196	0.00105	CcSEcCtD
Irbesartan—Anorexia—Prednisone—Crohn's disease	0.000193	0.00104	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000185	0.000992	CcSEcCtD
Irbesartan—Paraesthesia—Prednisone—Crohn's disease	0.000182	0.000978	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—Crohn's disease	0.000179	0.000958	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—Crohn's disease	0.000176	0.000946	CcSEcCtD
Irbesartan—Fatigue—Prednisone—Crohn's disease	0.000175	0.000939	CcSEcCtD
Irbesartan—Constipation—Prednisone—Crohn's disease	0.000174	0.000931	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisone—Crohn's disease	0.000167	0.000897	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—Crohn's disease	0.000166	0.00089	CcSEcCtD
Irbesartan—Urticaria—Prednisone—Crohn's disease	0.000161	0.000865	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—Crohn's disease	0.00016	0.000861	CcSEcCtD
Irbesartan—Body temperature increased—Prednisone—Crohn's disease	0.00016	0.000861	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisone—Crohn's disease	0.00015	0.000802	CcSEcCtD
Irbesartan—Asthenia—Prednisone—Crohn's disease	0.000146	0.000781	CcSEcCtD
Irbesartan—Pruritus—Prednisone—Crohn's disease	0.000144	0.00077	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—Crohn's disease	0.000139	0.000745	CcSEcCtD
Irbesartan—Dizziness—Prednisone—Crohn's disease	0.000134	0.00072	CcSEcCtD
Irbesartan—Vomiting—Prednisone—Crohn's disease	0.000129	0.000692	CcSEcCtD
Irbesartan—Rash—Prednisone—Crohn's disease	0.000128	0.000686	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—Crohn's disease	0.000128	0.000686	CcSEcCtD
Irbesartan—Headache—Prednisone—Crohn's disease	0.000127	0.000682	CcSEcCtD
Irbesartan—Nausea—Prednisone—Crohn's disease	0.000121	0.000647	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—MTMR3—Crohn's disease	0.000114	0.000603	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CCR6—Crohn's disease	0.000113	0.000599	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000112	0.000594	CbGpPWpGaD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—Crohn's disease	0.000111	0.000591	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	0.00011	0.000585	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—JAK2—Crohn's disease	0.000109	0.00058	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000109	0.000579	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GPR65—Crohn's disease	0.000109	0.000575	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL3—Crohn's disease	0.000108	0.000573	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—Crohn's disease	0.000108	0.000572	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000108	0.000572	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL1B—Crohn's disease	0.000107	0.000564	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—STAT3—Crohn's disease	0.000106	0.000562	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL1B—Crohn's disease	0.000106	0.000561	CbGpPWpGaD
Irbesartan—JUN—Immune System—CARD9—Crohn's disease	0.000106	0.000561	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RSPO3—Crohn's disease	0.000106	0.00056	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000105	0.000556	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000105	0.000554	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ACKR2—Crohn's disease	0.000104	0.000552	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000104	0.00055	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL6—Crohn's disease	0.000104	0.00055	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCR6—Crohn's disease	0.000103	0.000544	CbGpPWpGaD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—IL6—Crohn's disease	0.000101	0.000534	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SEL1L—Crohn's disease	0.0001	0.000531	CbGpPWpGaD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—Crohn's disease	9.99e-05	0.000529	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—IL1B—Crohn's disease	9.99e-05	0.000529	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PTGER4—Crohn's disease	9.96e-05	0.000528	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	9.9e-05	0.000524	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MLN—Crohn's disease	9.87e-05	0.000523	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL3—Crohn's disease	9.82e-05	0.00052	CbGpPWpGaD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—IL6—Crohn's disease	9.81e-05	0.00052	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	9.69e-05	0.000513	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL6—Crohn's disease	9.63e-05	0.00051	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—CXCL8—Crohn's disease	9.6e-05	0.000508	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—UBE2D1—Crohn's disease	9.55e-05	0.000506	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—RASGRP1—Crohn's disease	9.49e-05	0.000503	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	9.49e-05	0.000503	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—STAT3—Crohn's disease	9.47e-05	0.000502	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—IL6—Crohn's disease	9.47e-05	0.000502	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—IL6—Crohn's disease	9.47e-05	0.000502	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	9.35e-05	0.000495	CbGpPWpGaD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—IL6—Crohn's disease	9.3e-05	0.000493	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	9.3e-05	0.000493	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—RIPK2—Crohn's disease	9.26e-05	0.00049	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCR9—Crohn's disease	9.16e-05	0.000485	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PTGER4—Crohn's disease	9.04e-05	0.000479	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TAGAP—Crohn's disease	9.03e-05	0.000478	CbGpPWpGaD
Irbesartan—JUN—MyD88-independent cascade—IL6—Crohn's disease	8.93e-05	0.000473	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	8.9e-05	0.000472	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	8.88e-05	0.00047	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—FADS1—Crohn's disease	8.87e-05	0.00047	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	8.83e-05	0.000468	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—RASGRP1—Crohn's disease	8.73e-05	0.000463	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL6—Crohn's disease	8.72e-05	0.000462	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—STAT3—Crohn's disease	8.62e-05	0.000457	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TAB1—Crohn's disease	8.54e-05	0.000453	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—IL6—Crohn's disease	8.52e-05	0.000451	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL6—Crohn's disease	8.52e-05	0.000451	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GPR65—Crohn's disease	8.52e-05	0.000451	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—Crohn's disease	8.49e-05	0.00045	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL3—Crohn's disease	8.48e-05	0.000449	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	8.47e-05	0.000449	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—Crohn's disease	8.43e-05	0.000447	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NOD2—Crohn's disease	8.39e-05	0.000445	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GPX4—Crohn's disease	8.3e-05	0.00044	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CXCL8—Crohn's disease	8.22e-05	0.000436	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—RASGRP1—Crohn's disease	8.2e-05	0.000435	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	8.19e-05	0.000434	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—IL6—Crohn's disease	8.03e-05	0.000426	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GCKR—Crohn's disease	8.02e-05	0.000425	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—SOCS1—Crohn's disease	7.91e-05	0.000419	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RSPO3—Crohn's disease	7.89e-05	0.000418	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCR6—Crohn's disease	7.73e-05	0.00041	CbGpPWpGaD
Irbesartan—JUN—Immune System—NOD1—Crohn's disease	7.72e-05	0.000409	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—STAT3—Crohn's disease	7.72e-05	0.000409	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL3—Crohn's disease	7.7e-05	0.000408	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—Crohn's disease	7.69e-05	0.000407	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	7.6e-05	0.000403	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL2RA—Crohn's disease	7.57e-05	0.000401	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	7.57e-05	0.000401	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—IL6—Crohn's disease	7.55e-05	0.0004	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PLA2G4F—Crohn's disease	7.54e-05	0.000399	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SEL1L—Crohn's disease	7.48e-05	0.000396	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—RASGRP1—Crohn's disease	7.45e-05	0.000395	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CXCL8—Crohn's disease	7.25e-05	0.000384	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—Crohn's disease	7.25e-05	0.000384	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	7.24e-05	0.000384	CbGpPWpGaD
Irbesartan—JUN—Immune System—CCR6—Crohn's disease	7.01e-05	0.000372	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RBX1—Crohn's disease	6.99e-05	0.000371	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL2RA—Crohn's disease	6.88e-05	0.000364	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL6—Crohn's disease	6.85e-05	0.000363	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCR9—Crohn's disease	6.84e-05	0.000363	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTGER4—Crohn's disease	6.81e-05	0.000361	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL6—Crohn's disease	6.8e-05	0.000361	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	6.78e-05	0.000359	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—IL6—Crohn's disease	6.73e-05	0.000356	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	6.54e-05	0.000346	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	6.47e-05	0.000343	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CXCL8—Crohn's disease	6.45e-05	0.000342	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	6.43e-05	0.00034	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTPN2—Crohn's disease	6.41e-05	0.00034	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MTMR3—Crohn's disease	6.41e-05	0.00034	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	6.4e-05	0.000339	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	6.4e-05	0.000339	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GPR65—Crohn's disease	6.36e-05	0.000337	CbGpPWpGaD
Irbesartan—JUN—Immune System—RBX1—Crohn's disease	6.34e-05	0.000336	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL6—Crohn's disease	6.24e-05	0.00033	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL6—Crohn's disease	6.2e-05	0.000329	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—UBE2D1—Crohn's disease	6.13e-05	0.000325	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCR6—Crohn's disease	6.07e-05	0.000321	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CRP—Crohn's disease	5.97e-05	0.000316	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RIPK2—Crohn's disease	5.95e-05	0.000315	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2RA—Crohn's disease	5.94e-05	0.000315	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	5.89e-05	0.000312	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—STAT3—Crohn's disease	5.83e-05	0.000309	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL3—Crohn's disease	5.8e-05	0.000307	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TLR4—Crohn's disease	5.72e-05	0.000303	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	5.61e-05	0.000297	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RASGRP1—Crohn's disease	5.61e-05	0.000297	CbGpPWpGaD
Irbesartan—JUN—Immune System—UBE2D1—Crohn's disease	5.56e-05	0.000295	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.52e-05	0.000292	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RBX1—Crohn's disease	5.49e-05	0.000291	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2RA—Crohn's disease	5.4e-05	0.000286	CbGpPWpGaD
Irbesartan—JUN—Immune System—RIPK2—Crohn's disease	5.39e-05	0.000286	CbGpPWpGaD
Irbesartan—JUN—Immune System—ITGA4—Crohn's disease	5.39e-05	0.000286	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL6—Crohn's disease	5.39e-05	0.000286	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTGER4—Crohn's disease	5.34e-05	0.000283	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL3—Crohn's disease	5.26e-05	0.000279	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—JAK2—Crohn's disease	5.09e-05	0.00027	CbGpPWpGaD
Irbesartan—JUN—Immune System—RASGRP1—Crohn's disease	5.09e-05	0.000269	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SOCS1—Crohn's disease	5.08e-05	0.000269	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD79A—Crohn's disease	5.07e-05	0.000269	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—IL6—Crohn's disease	5.07e-05	0.000268	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	5.04e-05	0.000267	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—FADS1—Crohn's disease	4.99e-05	0.000265	CbGpPWpGaD
Irbesartan—JUN—Immune System—TAB1—Crohn's disease	4.98e-05	0.000264	CbGpPWpGaD
Irbesartan—JUN—Immune System—NOD2—Crohn's disease	4.89e-05	0.000259	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PLA2G4F—Crohn's disease	4.87e-05	0.000258	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—TYK2—Crohn's disease	4.84e-05	0.000257	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—UBE2D1—Crohn's disease	4.81e-05	0.000255	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	4.72e-05	0.00025	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GPX4—Crohn's disease	4.68e-05	0.000248	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RIPK2—Crohn's disease	4.67e-05	0.000247	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CXCL8—Crohn's disease	4.64e-05	0.000246	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—JAK2—Crohn's disease	4.62e-05	0.000245	CbGpPWpGaD
Irbesartan—JUN—Immune System—SOCS1—Crohn's disease	4.61e-05	0.000244	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL3—Crohn's disease	4.55e-05	0.000241	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCR6—Crohn's disease	4.53e-05	0.00024	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GCKR—Crohn's disease	4.52e-05	0.000239	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TYK2—Crohn's disease	4.46e-05	0.000236	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RASGRP1—Crohn's disease	4.4e-05	0.000233	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SMAD3—Crohn's disease	4.39e-05	0.000232	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—JAK2—Crohn's disease	4.25e-05	0.000225	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCL8—Crohn's disease	4.22e-05	0.000223	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL18—Crohn's disease	4.15e-05	0.00022	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTMR3—Crohn's disease	4.14e-05	0.000219	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RBX1—Crohn's disease	4.1e-05	0.000217	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—IL6—Crohn's disease	4.07e-05	0.000216	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2RA—Crohn's disease	4.06e-05	0.000215	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD4—Crohn's disease	4.03e-05	0.000213	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	4e-05	0.000212	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—JAK2—Crohn's disease	3.99e-05	0.000212	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTGER4—Crohn's disease	3.99e-05	0.000211	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SOCS1—Crohn's disease	3.99e-05	0.000211	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	3.96e-05	0.00021	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TYK2—Crohn's disease	3.8e-05	0.000201	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2RA—Crohn's disease	3.68e-05	0.000195	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCL8—Crohn's disease	3.64e-05	0.000193	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—JAK2—Crohn's disease	3.63e-05	0.000192	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—UBE2D1—Crohn's disease	3.59e-05	0.00019	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RIPK2—Crohn's disease	3.49e-05	0.000185	CbGpPWpGaD
Irbesartan—JUN—Immune System—CRP—Crohn's disease	3.47e-05	0.000184	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SMAD3—Crohn's disease	3.44e-05	0.000182	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL3—Crohn's disease	3.4e-05	0.00018	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTMR3—Crohn's disease	3.4e-05	0.00018	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	3.39e-05	0.000179	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTMR3—Crohn's disease	3.37e-05	0.000179	CbGpPWpGaD
Irbesartan—JUN—Immune System—TLR4—Crohn's disease	3.33e-05	0.000176	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL8—Crohn's disease	3.31e-05	0.000175	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RASGRP1—Crohn's disease	3.29e-05	0.000174	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	3.23e-05	0.000171	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—FADS1—Crohn's disease	3.23e-05	0.000171	CbGpPWpGaD
Irbesartan—JUN—Immune System—ICAM1—Crohn's disease	3.19e-05	0.000169	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2RA—Crohn's disease	3.19e-05	0.000169	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GPX4—Crohn's disease	3.02e-05	0.00016	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SOCS1—Crohn's disease	2.98e-05	0.000158	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GCKR—Crohn's disease	2.92e-05	0.000155	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTMR3—Crohn's disease	2.88e-05	0.000153	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TYK2—Crohn's disease	2.86e-05	0.000152	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.82e-05	0.00015	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—JAK2—Crohn's disease	2.73e-05	0.000145	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—FADS1—Crohn's disease	2.65e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—FADS1—Crohn's disease	2.63e-05	0.000139	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	2.61e-05	0.000138	CbGpPWpGaD
Irbesartan—JUN—Immune System—TYK2—Crohn's disease	2.6e-05	0.000137	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMAD3—Crohn's disease	2.57e-05	0.000136	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ALB—Crohn's disease	2.55e-05	0.000135	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—Crohn's disease	2.49e-05	0.000132	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GPX4—Crohn's disease	2.48e-05	0.000131	CbGpPWpGaD
Irbesartan—JUN—Immune System—JAK2—Crohn's disease	2.48e-05	0.000131	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GPX4—Crohn's disease	2.46e-05	0.00013	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNG—Crohn's disease	2.43e-05	0.000129	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GCKR—Crohn's disease	2.39e-05	0.000127	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2RA—Crohn's disease	2.38e-05	0.000126	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GCKR—Crohn's disease	2.37e-05	0.000126	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—Crohn's disease	2.37e-05	0.000126	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD4—Crohn's disease	2.35e-05	0.000124	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TYK2—Crohn's disease	2.25e-05	0.000119	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—FADS1—Crohn's disease	2.24e-05	0.000119	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—Crohn's disease	2.23e-05	0.000118	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTMR3—Crohn's disease	2.22e-05	0.000118	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—Crohn's disease	2.18e-05	0.000115	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1B—Crohn's disease	2.17e-05	0.000115	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JAK2—Crohn's disease	2.14e-05	0.000114	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GPX4—Crohn's disease	2.1e-05	0.000111	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	2.08e-05	0.00011	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GCKR—Crohn's disease	2.03e-05	0.000107	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—Crohn's disease	2e-05	0.000106	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—Crohn's disease	1.96e-05	0.000104	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—Crohn's disease	1.86e-05	9.85e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.82e-05	9.66e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—Crohn's disease	1.82e-05	9.63e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FADS1—Crohn's disease	1.73e-05	9.17e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.7e-05	8.99e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TYK2—Crohn's disease	1.68e-05	8.89e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPX4—Crohn's disease	1.62e-05	8.59e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—JAK2—Crohn's disease	1.6e-05	8.48e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—Crohn's disease	1.57e-05	8.33e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GCKR—Crohn's disease	1.57e-05	8.3e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.48e-05	7.86e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—Crohn's disease	1.46e-05	7.74e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.45e-05	7.68e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—Crohn's disease	1.44e-05	7.62e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—Crohn's disease	1.4e-05	7.42e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—Crohn's disease	1.27e-05	6.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.27e-05	6.72e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—Crohn's disease	1.26e-05	6.66e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—Crohn's disease	1.17e-05	6.22e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—Crohn's disease	1.1e-05	5.82e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—Crohn's disease	9.28e-06	4.92e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—Crohn's disease	8.21e-06	4.35e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—Crohn's disease	8.12e-06	4.3e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—Crohn's disease	7.62e-06	4.04e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—Crohn's disease	7.56e-06	4e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—Crohn's disease	6.67e-06	3.53e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—Crohn's disease	6.61e-06	3.5e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—Crohn's disease	6.46e-06	3.42e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—Crohn's disease	5.65e-06	2.99e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—Crohn's disease	4.98e-06	2.64e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—Crohn's disease	4.36e-06	2.31e-05	CbGpPWpGaD
